US Supreme Court A court on Friday temporarily stayed a lower court order banning the abortion drug mifepristone. This action means that the drug will remain available and legal under current regulations until the lawsuit goes through the appeals process. This may take several months.
The court’s final ruling may be the most significant ruling since overturning the reproductive rights ruling. Law vs Wade June 2022.
Mifepristone has been available in the United States since 2000 when the US Food and Drug Administration approved it for use. This is the first dose in a series of two drugs used in medical abortions, which now account for more than half of all abortions nationwide. Access to medical abortion is already restricted in 15 states.
But on April 7, Judge Matthew Kaksmarik of the Northern District of Texas ruled to revoke the approval of the pill nationwide. The plaintiff in the case, an anti-abortion doctor, argued that FDA approval was inappropriate because the drug was unsafe and pregnancy was not a disease. But the drug has a decades-long track record of safety, and a comprehensive review conducted by the National Academy of Sciences confirms a very low incidence of serious complications. .
The following week, the Court of Appeals for the Fifth Circuit partially blocked Kacsmaryk’s decision, allowing the pill to remain FDA approved, but rolled back several changes the FDA had made in recent years to allow the pill to continue. expanded access to Among these were pandemic-era provisions that made it easier to prescribe mifepristone online and distribute it by mail, and a 2016 change that allowed the pill to be taken up to 10 weeks pregnant.
The US Department of Justice, acting on behalf of the FDA, and New York-based Danco Laboratories, which manufactures mifepristone, have asked the judge to intervene. Over the past week, the Supreme Court has issued two separate short-term stays to consider this issue. The court, which had set a deadline until midnight Wednesday to decide whether Pill would face tougher rules while the appeal is ongoing, has extended that deadline to today.
GenBioPro, the generic drug maker of mifepristone, joined the fray this week by filing a lawsuit against the FDA. If Mifepristone’s approval is revoked, the generic version of GenBioPro will also be stopped. The company argues that if the FDA follows his Kacsmaryk ruling, it would be violating established legal processes for discontinuing use of previously approved drugs.
“We have very detailed procedures to take drugs off the market,” says Ameet Sarpatwari, an attorney and assistant professor of medicine at Harvard Medical School. Kacsmaryk’s ruling sidesteps that established process, Sarpatwari said. Manufacturers and the FDA have historically removed drugs from the market, citing low demand or risk to patients, but courts stepped in to stop the use of long-approved drugs. I never did.
Pharmaceutical companies and pharmaceutical companies say the lower court’s ruling is an unprecedented violation of FDA’s authority. This agency is tasked with reviewing, approving, and regulating the safety and efficacy of medicines. They say that if mifepristone were banned or restricted, other drugs would be at risk, especially those subject to political opposition such as hormonal contraceptives, HIV preventatives, and vaccines.
More than 600 executives from biotech and pharmaceutical companies have signed a letter warning that withdrawing mifepristone from the market would have a chilling effect on innovation. Companies often spend billions of dollars to get drugs through their development pipelines and hate seeing courts void their investments. Investment may decline because there is uncertainty about whether it will happen,” says Sarpatwari.
